

# SHANGQING (JOYCE) JIANG

## HEOR SCIENTIST, MARKET ACCESS STRATEGIST

607- 373-7433 ▪ sjiang93@uw.edu ▪ Seattle, WA

### PROFESSIONAL SUMMARY

HEOR PhD with deep knowledge of US healthcare system and global HTA. Strong analytical skills in AI, ML, and RWE. Three+ years of experience in pharma industry in market access, business development, RWE, data science, and health economics. First-rate written and oral communication skills. F1 OPT as work authorization. Start date: Summer 2024.

### SKILLS

- Health economic modeling
- Machine learning, artificial intelligence
- Real-world data analytics and coding
- Market research and competitive analysis

### EXPERIENCE

#### ■ VENTURE CAPITAL ASSOCIATE INTERN Kendall Capital Partners

*April 2023 - January 2024*

- Screened 200+ startups and made initial recommendations to the investment team, led 2 deals by due diligence, completed investment memos and reported to the investment committee, closed 1 deal with \$2M investment
- Interview 20+ healthcare PhD students as intern candidates, assigned deals to interns and oversaw interns' performance
- Orchestrated portfolio companies raise capital in the current and next rounds, answered questions from potential syndicates
- Organized 2023 Annual Investor Meeting at Boston in Nov 2023, hosted events for existing and potential limited partners (LPs)

#### ■ BUSINESS DEVELOPMENT FELLOW Genentech

*August 2023 - October 2023*

- Conducted Search and Evaluation on therapeutics to treat CNS diseases, identified and screened 100+ biotech startups, created a library that included 40+ biotech companies in CNS disease landscape
- Identified 1 startup as a potential collaborator, performed due diligence, made a partnership recommendation to the Genentech BD team

#### ■ HEALTH ECONOMICS INTERN Merck & Co., Inc.

*June 2022 - September 2022*

- Researched UK NICE's latest HTA requirement on disease severity, modeled the change of cost-effectiveness of Keytruda in oncology indications, informed the Market Access team regarding potential changes in pricing strategies
- Systematically reviewed economic models at UK NICE 2019-2022 and summarized lessons learned, made recommendations to the Modeling team
- Comprehensively examined the use of RWE in re-appraisals at UK NICE, US ICER and Canada CADTH, informed the Evidence team regarding study planning
- Received the "Innovation and Scientific Excellence Award"

■ **HEALTH ECONOMICS CONSULTANT** VeriTech Inc.

*April 2021 - December 2021*

- Performed systematic literature review on real-world evidence of approved Hepatitis B drugs and identified knowledge gaps in clinical care
- Informed the cost-effectiveness model in Excel with clinical and economic evidence to assess the value of 2 new Hepatitis B drugs, made recommendations to the Commercial Business Unit regarding the pricing strategies

■ **DATA SCIENCE INTERN** BioMarin Pharmaceutical Inc.

*June 2021 - September 2021*

- Conducted targeted reviews on the use of wearable devices in clinical trials, made recommendations to the Data Science team regarding computational and statistical challenges
- Compared 3 statistical simulation methods to extrapolate survivals in health economic modeling, examined the impact on the cost-effectiveness of orphan drugs

■ **HEALTH ECONOMICS & MARKET ACCESS INTERN** Illumina, Inc.

*June 2020 - August 2020*

- Systematically reviewed clinical and economic evidence of genetic prenatal testing and identified evidence gaps for the Market Access team
- Gathered clinical evidence of whole genome sequencing in multiple cancers to inform economic models
- Analyzed HCUP claims data to assess utilization and costs in pediatric genetic diseases, informed the Market Access team about the market size of genetic diseases
- Conducted a targeted review on costs of whole-genome sequencing for labs, identified financial challenges and opportunities of labs for the Market Access team

■ **GRADUATE RESEARCH ASSISTANT** University of Washington

*September 2019 - Present*

Value of Polygenic Risk Scores in Colorectal Cancer Screening. PI: Dave Veenstra

- Built machine learning models in R that used genomic information to improve colorectal cancer risk prediction
- Constructed a cost-effectiveness model in Excel that assessed the value of colorectal cancer risk prediction algorithms in guiding personalized screening and early detection

Rural Disparity in Atrial Fibrillation and Catheter Ablation. PI: Ryan Hansen

- Designed a study plan and statistical analysis protocol to assess the rural disparities in atrial fibrillation and catheter ablation
- Analyzed MarketScan claims data in SAS and R to evaluate rural disparity in atrial fibrillation

Value of Care in Alzheimer's Diseases. PI: Doug Barthold

- Conducted literature review on the utilization of low- and high-value care in different disease areas
- Performed longitudinal analysis in STATA on Medicare claims data and Health and Retirement Study (HRS) data

Cost-effectiveness of Genomic Screening on Lynch Syndrome. PI: Dave Veenstra

- Comprehensively examined economic models on Lynch Syndrome screening, identified critical knowledge gaps and informed the study design
- Synthesized clinical and economic evidence in Lynch Syndrome and informed the cost-effectiveness model in Excel

Meta-analysis of Pharmacist-led Interventions on Medication Adherence. PI: Zach Marcum

- Screened 3000+ articles found by search, extracted relevant information from 50+ articles
- Systematically reviewed the limitations of existing literature, informed the meta-analysis plan

Value of Clinical Decision Support on Pharmacogenomic Testing. PI: Beth Devine

- Built a cost-effectiveness model in R to assess the value of Clinical Decision Support to prevent cardiovascular events
- Analyzed MarketScan claims data to derive the utilization of treatments in cardiovascular diseases and informed the model

## EDUCATION

### PHD IN HEALTH ECONOMICS AND OUTCOMES RESEARCH

University of Washington

*Expected graduation June 2024*

#### *Awards & Honors*

- PhRMA Foundation Predoctoral Fellowship in Health Outcomes Research (2022)
- UW Graduate School Top Scholar Award (2019)
- ISPOR Travel Grant Award (2022)
- UW Rubenstein Endowment Award (2020-2023)

#### *Extracurricular Activities*

- Graduate Certificate in Entrepreneurship at Foster School of Business
- Recipient of The Best Idea in Digital Health Award at Hollomon Health Innovation Challenge 2023

### MPH IN EPIDEMIOLOGY

Columbia University

*May 2019*

### BS IN EXPERIMENTAL MEDICINE, BA IN ECONOMICS

Peking University

*July 2015*

#### *Awards & Honors*

- Outstanding Undergraduate Student of the Class 2015 of Beijing (top <1%)
- Outstanding Undergraduate Student of the Class 2015 of Peking University (top <1%)

## HYPERLINKS

LinkedIn: <http://www.linkedin.com/in/sqjiang/>

## PUBLICATIONS

- Full publications and presentations can be found: <https://scholar.google.com/citations?user=5TRrQbAAAAAJ&hl=en>
- Jiang S, Seslar SP, Sloan LA, Hansen RN. Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities. *J Manag Care Spec Pharm.* 2022;28(11):1321-1330. doi:10.18553/jmcp.2022.28.11.1321
- Guzauskas GF, Jiang S (co-first author), Garbett S, et al. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States. *Genet Med.* 2022;24(5):1017-1026. doi:10.1016/j.gim.2022.01.017
- Barthold D, Jiang S, Basu A, et al. Utilization of low- and high-value healthcare by individuals with and without cognitive impairment. Accepted by *AJMC*